Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma
European Journal of Cancer2020Vol. 135, pp. 31–38
Citations Over Time
Lu Si, Xiaoshi Zhang, Sang Joon Shin, Yun Fan, Chia‐Chi Lin, Tae Min Kim, Arunee Dechaphunkul, Jedzada Maneechavakajorn, Chi Sing Frank Wong, Palanichamy Ilankumaran, Yong Sang Lee, Eduard Gasal, Haifu Li, Jun Guo
Related Papers
- → Trametinib: a MEK inhibitor for management of metastatic melanoma(2015)177 cited
- → Trametinib in the treatment of melanoma(2015)39 cited
- → Dabrafenib–trametinib combination therapy re-challenge in advanced BRAFV600E-mutant non–small-cell lung cancer(2020)12 cited
- → BRAF and MEK Inhibitors Approved for Melanoma(2013)1 cited
- → The MEK inhibitor trametinib for the treatment of advanced melanoma(2014)